Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis

Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis …………… Yu RZ, Collins JW, Hall S, Ackermann EJ, Geary RS, Monia BP, Henry SP, Wang Y. Nucleic Acid Ther. 2020 Apr 15. PubMed

Reverse Transcription Quantitative Polymerase Chain Reaction Methods to Support Pharmacokinetics and Drug Mechanism of Action to Advance Development of RNA Interference Therapeutics

Reverse Transcription Quantitative Polymerase Chain Reaction Methods to Support Pharmacokinetics and Drug Mechanism of Action to Advance Development of RNA Interference Therapeutics …………… Castellanos-Rizaldos E, Brown CR, Dennin S, Kim J, Gupta S, Najarian D, Gu Y, Aluri K, Enders J, Brown K, Xu Y. Nucleic Acid Ther. 2020 Mar 23. PubMed

Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis.

Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis. …………… Sutherland JE, Hettinger JL, Chan A, Gilbert J, Warner GL, Davis WP. Nucleic Acid Ther. 2019 Dec 10. PubMed